This single-arm, open-label trial evaluates the safety and efficacy of the anti–epidermal growth factor receptor antibody panitumumab plus neoadjuvant chemotherapy (nab-paclitaxel and carboplatin followed by fluorouracil, epirubicin, and cyclophosphamide) in patients with primary HER2-negative inflammatory breast cancer.
https://ift.tt/2M5Drap
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου